Long-Acting Injectable HIV PrEP PROs
ConditionHIV Pre-exposure Prophylaxis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAnupama Raghuram MD
About this trial
The goal of this observational study is to learn about the real world effectiveness, patient satisfaction and clinical outcomes of LAI PrEP with lenacapavir (LEN) versus cabotegravir (CAB) through surveys and interviews.
Participants receiving or initiating LAI PrEP part of their regular medical care will complete surveys and interviews at three study visits over the course of 12 months.
Eligibility criteria
Qualifiers
Adults aged 18 and older
Deemed eligible for HIV PrEP per healthcare provider
Current use of CAB or LEN LAI PrEP at study entry
Initiation of either CAB or LEN LAI PrEP within 30 days of study enrollment
Disqualifiers
HIV diagnosis prior to enrollment
Currently on oral PrEP with no plans to switch to LAI PrEP
Hypersensitivities to LEN or CAB
Pregnant or planning to become pregnant
Trial design
Treatments tested in this trial
- Interview and survey to evaluate patient reported outcomes between the two medications.
Treatment groups
128 Participants
are divided into 2 treatment groupsSponsors and collaborators
Anupama Raghuram MD
Lead sponsor
Norton Healthcare
Sponsor institution
Gilead Sciences
Collaborator
University of Louisville
Collaborator
Source ClinicalTrials.gov